Brainstem Glioma in Adults

Brainstem gliomas are not nearly as common in adults as they are in children. They are likely the final common consequence not of a single disease process but of several. They can be difficult to diagnose, and are challenging to treat. Clinical studies of this diagnosis are few and generally small. Because of these factors, our understanding of the biology of adult brainstem glioma is incomplete. However, the knowledge base is growing and progress is being made. In this article, we review the current state of knowledge for brainstem glioma in adults and identify key areas for which additional information is required.

[1]  D. Reardon,et al.  Adult brainstem gliomas , 2016, Cancer.

[2]  Shawn M. Gillespie,et al.  Insulator dysfunction and oncogene activation in IDH mutant gliomas , 2015, Nature.

[3]  Ranadip Pal,et al.  Erratum: Functionally defined therapeutic targets in diffuse intrinsic pontine glioma , 2015, Nature Medicine.

[4]  M. Couce,et al.  Histologically Proven Radiation‐Induced Brainstem Glioma 93 Months After External Beam Radiotherapy for Pituitary Macroadenoma: Radiation Treatment Dose and Volume Correlation , 2015, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[5]  Steven J. M. Jones,et al.  Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. , 2015, The New England journal of medicine.

[6]  K. Aldape,et al.  Adult brainstem gliomas: Correlation of clinical and molecular features , 2015, Journal of the Neurological Sciences.

[7]  Nicholas J. Wang,et al.  Functionally-defined Therapeutic Targets in Diffuse Intrinsic Pontine Glioma , 2015, Nature Medicine.

[8]  M. Remke,et al.  An epigenetic therapy for diffuse intrinsic pontine gliomas , 2014, Nature Medicine.

[9]  C. James,et al.  Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma , 2014, Nature Medicine.

[10]  N. Martin-Duverneuil,et al.  Temozolomide after radiotherapy in recurrent “low grade” diffuse brainstem glioma in adults , 2014, Journal of Neuro-Oncology.

[11]  R. McLendon,et al.  Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas , 2014, Nature Genetics.

[12]  M. Prados,et al.  A phase 1 study of AZD6244 in children with recurrent or refractory low-grade gliomas: A Pediatric Brain Tumor Consortium report. , 2014 .

[13]  R. McLendon,et al.  Malignant brainstem gliomas in adults: clinicopathological characteristics and prognostic factors , 2014, Journal of Neuro-Oncology.

[14]  Amar Gajjar,et al.  The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma , 2014, Nature Genetics.

[15]  Stephen Yip,et al.  Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma , 2014, Nature Genetics.

[16]  Michael Brudno,et al.  Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations , 2014, Nature Genetics.

[17]  R. McLendon,et al.  Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study. , 2014, Neuro-oncology.

[18]  P. Kearns,et al.  Diffuse intrinsic pontine glioma treated with prolonged temozolomide and radiotherapy – Results of a United Kingdom phase II trial (CNS 2007 04) , 2013, European journal of cancer.

[19]  S. Muzumder,et al.  Re-irradiation with hypo-fractionated stereotactic robotic radiotherapy for salvage in adult patients with brainstem glioma , 2013, ecancermedicalscience.

[20]  S. Baylin,et al.  5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft , 2013, Oncotarget.

[21]  C. Brennan,et al.  Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine , 2013, Oncotarget.

[22]  K. Stegmaier,et al.  Targeting MYCN in neuroblastoma by BET bromodomain inhibition. , 2013, Cancer discovery.

[23]  David T. W. Jones,et al.  Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma , 2012, Nature.

[24]  Li Ding,et al.  Somatic Histone H3 Alterations in Paediatric Diffuse Intrinsic Pontine Gliomas and Non-Brainstem Glioblastomas , 2012, Nature Genetics.

[25]  J. Uhm IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype , 2012 .

[26]  M. Souweidane,et al.  Proceedings of the diffuse intrinsic pontine glioma (DIPG) Toronto Think Tank: advancing basic and translational research and cooperation in DIPG , 2011, Journal of Neuro-Oncology.

[27]  U. Bode,et al.  Nimotuzumab for pediatric diffuse intrinsic pontine gliomas , 2011, Expert opinion on biological therapy.

[28]  P. Varlet,et al.  Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. , 2011, Neuro-oncology.

[29]  D. Johnston,et al.  A multi-centre Canadian pilot study of metronomic temozolomide combined with radiotherapy for newly diagnosed paediatric brainstem glioma. , 2010, European journal of cancer.

[30]  Amar Gajjar,et al.  Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  R. Gilbertson,et al.  Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  S. Ferman,et al.  Brainstem gliomas— Retrospective analysis of 86 patients , 2009, Journal of the Neurological Sciences.

[33]  T. MacDonald,et al.  Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors , 2009, Pediatric blood & cancer.

[34]  Ryung S. Kim,et al.  Prognostic factors in adult brainstem gliomas: a multicenter, retrospective analysis of 101 cases , 2008, Journal of Neuro-Oncology.

[35]  T. MacDonald,et al.  Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  T. Zhou,et al.  Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP‐16: A Children's Oncology Group phase II study , 2008, Pediatric blood & cancer.

[37]  T. Zhou,et al.  A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high‐grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: A children's oncology group study , 2007, Cancer.

[38]  P. Houghton,et al.  Phase I study of everolimus in pediatric patients with refractory solid tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  I. Pollack,et al.  Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  I. Pollack,et al.  Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. , 2007, Neuro-oncology.

[41]  J. Dancey,et al.  Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  D. Rating,et al.  Treatment of paediatric pontine glioma with oral trophosphamide and etoposide , 2002, British Journal of Cancer.

[43]  J J Mazeron,et al.  Brainstem gliomas in adults: prognostic factors and classification. , 2001, Brain : a journal of neurology.